Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

2018101 citationsJournal Articlegreen Open Access

Authors

Matteo Lambertini · Université Libre de Bruxelles

Christine Campbell · Frontier Agriculture (United Kingdom)

José Bines

Larissa A. Korde · National Cancer Institute

Miguel Izquierdo · Novartis (Switzerland)

Debora Fumagalli · Breast International Group

Lucia Del Mastro · Ospedale Policlinico San Martino

Abstract

In this unplanned analysis, no association between TRA rate and type of anti-HER2 treatment was observed. TRA was associated with statistically significant survival benefits in premenopausal hormone receptor-positive/HER2-positive early breast cancer patients.

Topics & Keywords

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 111, Issue 1, pp. 86-94

DOI: 10.1093/jnci/djy094

Field-Weighted Citation Impact: 4.73

Command Palette